Lantern Pharma Inc Stock Price, News & Analysis

Lantern Pharma (NASDAQ: LTRN) announced the U.S. Patent and Trademark Office has issued a notice of allowance for its patent application related to its drug candidate LP-284, targeting non-Hodgkin's lymphomas. This patent is expected to provide market exclusivity until 2039. The company plans to submit an Investigational New Drug (IND) application for LP-284 to the FDA in mid-2023 and commence a Phase 1 clinical trial later this year. LP-284, with nanomolar potency, addresses significant unmet needs among patients with mantle cell lymphoma (MCL) and double-hit lymphoma (DHL), presenting an estimated annual market potential of $1.2 billion. The candidate has also received Orphan Drug Designation from the FDA for MCL, enhancing its development pathway.

Lantern Pharma Inc. (NASDAQ: LTRN) has initiated the Phase 2 Harmonic™ clinical trial, dosing the first patient with its investigational drug LP-300 in combination with chemotherapy for never smokers with advanced non-small cell lung cancer (NSCLC). The trial aims to assess the overall and progression-free survival in 90 patients, with 60 receiving LP-300 and 30 on standard chemotherapy. Previous trials showed a 91% overall survival rate at two years for LP-300 patients compared to those on chemotherapy alone. The market potential for this demographic is estimated between $1.5 to $2.0 billion.

Lantern Pharma Inc. (NASDAQ: LTRN), a biopharmaceutical company utilizing its RADR® AI platform for oncology drug development, announced presentations at three upcoming events. CEO Panna Sharma will present on March 22 at the Rare Disease Innovation & Partnership Summit in Philadelphia, discussing AI in drug development. He will also participate in a free webinar on March 23, co-hosted by Science History Institute and American Chemical Society, focusing on AI's impact on drug discovery. Additionally, Peter Carr will moderate a session at the Genomics in Precision Oncology Xchange on April 5 in Boston, emphasizing clinical trial design.

For more information, visit www.lanternpharma.com.

Lantern Pharma (NASDAQ: LTRN) announced significant operational highlights and financial results for the fourth quarter and fiscal year 2022. The Harmonic™ clinical trial for never-smoker patients with non-small cell lung cancer (NSCLC) has activated 5 clinical sites across 12 locations, with patient enrollment expected in Q2 2023. The company also completed IND-enabling studies for drug candidates LP-184 and LP-284, with IND submissions planned for April and mid-2023, respectively. Lantern reported a cash position of $55.2 million as of December 31, 2022, and expects a cash runway into 2025. The formation of Starlight Therapeutics for CNS cancer treatments was also highlighted.

Lantern Pharma Inc. (NASDAQ: LTRN) announced its participation in the AACR Annual Meeting from April 14-19, 2023 in Orlando, FL. The company will present a poster titled LP-184, an acylfulvene class small molecule therapeutic, focusing on its synthetic lethality mechanism targeting DNA damage repair deficient cancers, affecting 25-30% of solid tumors. The presentation is scheduled for April 19, 2023, 9:00 a.m. – 12:30 p.m. ET. Lantern aims to advance LP-184 to a Phase 1 clinical trial by mid-2023. Additionally, a webinar on synthetic lethality will be held on March 21, 2023 featuring expert Zoltan Szallasi.